中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

经肝动脉化疗栓塞术联合射频消融治疗兔肝VX2肿瘤的效果分析

李浩 段旭华 韩新巍 任建庄 李凤尧 邝东林 李方正

引用本文:
Citation:

经肝动脉化疗栓塞术联合射频消融治疗兔肝VX2肿瘤的效果分析

DOI: 10.3969/j.issn.1001-5256.2018.04.017
基金项目: 

国家自然科学青年基金资助项目(81401494); 河南省科医学科技计划攻关项目(201403059); 

详细信息
  • 中图分类号: R735.7

Clinical effect of transarterial chemoembolization combined with radiofrequency ablation in treatment of rabbit VX2 liver tumors

Research funding: 

 

  • 摘要: 目的观察经肝动脉化疗栓塞术(TACE)联合射频消融(RFA)以及单独应用对兔肝VX2肿瘤的效果及病理学改变。方法将18只建模成功的荷瘤兔平均分为3组,每组6只:TACE+RFA治疗组(TACE后15 min采用RFA治疗),单独行TACE治疗组和单独行RFA治疗组。术后7 d处死实验兔,比较肿瘤区凝固性坏死区或出血性性梗死区的最大切面积,对比典型的病理切片。计量资料多组间比较采用方差分析,进一步两两比较采用LSD-t检验。结果 RFA组中1只实验兔死于术中气胸;术后2 d TACE+RFA组中1只实验兔死于大面积肝坏死。16只实验兔存活至观察点结束,实验成功率为88.9%(16/18)。TACE+RFA组中的凝固性坏死最大长径、短径和肿瘤细胞坏死率与其他2组比较,差异均有统计学意义(P值均<0.05)。病理分析显示,TACE+RFA组和其他组相比具有更多的血管栓塞及坏死区、较少的岛屿状存活肿瘤细胞群。结论 TACE+RFA较单独应用RFA和TACE能够收获更好的肿瘤毁损效果。

     

  • [1]HAN K, KIM JH.Transarterial chemoembolization in hepatocellular carcinoma treatment:Barcelona clinic liver cancer staging system[J].World J Gastroenterol, 2015, 21 (36) :10327-10335.
    [2]GAO HJ, CHEN MS.Radiofrequency ablation for the treatment of hepatocellular carcinoma[J].J Clin Hepatol, 2012, 28 (4) :249-252. (in Chinese) 高恒军, 陈敏山.原发性肝癌的射频消融治疗[J].临床肝胆病杂志, 2012, 28 (4) :249-252.
    [3]LI HL, JI WB, ZHAO R, et al.Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation:retrospective analysis[J].World J Gastroenterol, 2015, 21 (12) :3599-3606.
    [4]SPREAFICO C, CASCELLA T, FACCIORUSSO A, et al.Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads:clinical-radiological outcomes and safety profile[J].Cardiovasc Intervent Radiol, 2015, 38 (1) :129-134.
    [5]MURAKAMI T, ISHIMARU H, SAKAMOTO I, et al.Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma:rate and risk factors for local recurrence[J].Cardiovasc Intervent Radiol, 2007, 30 (4) :696-704.
    [6]IKEDA K, OSAKI Y, NAKANISHI H, et al.Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma[J].Oncology, 2014, 87 (Suppl 1) :73-77.
    [7]LYU TS, ZOU YH, WANG J, et al.Current status of transcatheter arterial chemoembolization combined with radiofrequency ablation in treatment of primary liver cancer[J].J Clin Hepatol, 2016, 32 (1) :49-55. (in Chinese) 吕天石, 邹英华, 王健, 等.经肝动脉化疗栓塞术联合射频消融治疗原发性肝癌的现状[J].临床肝胆病杂志, 2016, 32 (1) :49-55.
    [8]SONG J, WANG Y, MA K, et al.Laparoscopic hepatectomy versus radiofrequency ablation for minimally invasive treatment of single, small hepatocellular carcinomas[J].Surg Endosc, 2016, 30 (10) :4249-4257.
    [9]BIMONTE S, LEONGITO M, PICCIRILLO M, et al.Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment[J].Infect Agent Cancer, 2016, 11:38.
    [10]DUAN XH, LI TF, ZHOU GF, et al.Transcatheter arterial embolization combined with radiofrequency ablation activates CD8+T-cell infiltration surrounding residual tumors in the rabbit VX2 liver tumors[J].Onco Targets Ther, 2016, 9:2835-2844.
    [11]ROSSI S, GARBAGNATI F, LENCIONI R, et al.Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply[J].Radiology, 2000, 217 (1) :119-126.
    [12]MOSTAFA EM, GANGULI S, FAINTUCH S, et al.Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors[J].J Vasc Interv Radiol, 2008, 19 (12) :1740-1748.
    [13]IEZZI R, POMPILI M, POSA A, et al.Combined locoregional treatment of patients with hepatocellular carcinoma:state of the art[J].World J Gastroenterol, 2016, 22 (6) :1935-1942.
    [14]WU HP, LIANG HM, ZHENG CS, et al.Lipiodol flowing into portal vein after hepatic artery embolization:the influential factors and its clinical significance[J].J Clin Radiol, 2005, 24 (5) :429-433. (in Chinese) 吴汉平, 梁惠民, 郑传胜, 等.肝动脉栓塞碘油进入门静脉的相关因素及其临床意义[J].临床放射学杂志, 2005, 24 (5) :429-433.
    [15]LENCIONI R, CROCETTI L, PETRUZZI P, et al.Doxorubicineluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma:a pilot clinical study[J].J Hepatol, 2008, 49 (2) :217-222.
    [16]KONG G, ANYARAMBHATLA G, PETROS WP, et al.Efficacy of liposomes and hyperthermia in a human tumor xenograft model:importance of triggered drug release[J].Cancer Res, 2000, 60 (24) :6950-6957.
    [17]HIGUCHI T, KIKUCHI M, OKAZAKI M.Hepatocellular carcinoma after transcatheter hepatic arterial embolization.A histopathologic study of 84 resected cases[J].Cancer, 1994, 73 (9) :2259-2267.
    [18]DUDAR TE, JAIN RK.Differential response of normal and tumor microcirculation to hyperthermia[J].Cancer Res, 1984, 44 (2) :605-612.
  • 加载中
计量
  • 文章访问数:  2204
  • HTML全文浏览量:  13
  • PDF下载量:  404
  • 被引次数: 0
出版历程
  • 出版日期:  2018-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回